Percheron Therapeutics Limited (FRA:AWY0)

Market Cap	4.68M -29.7%
Revenue (ttm)	510.83K -53.2%
Net Income	-2.90M
EPS	-0.00
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	0.0005
Previous Close	0.0005
Day's Range	0.0005 - 0.0005
52-Week Range	0.0005 - 0.0045
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 2, 2026

About Percheron Therapeutics

Percheron Therapeutics Limited engages in the research and development of antisense pharmaceuticals for cancer and rare diseases in Australia. Its products pipeline includes HMBD-002, a recombinant humanised monoclonal IgG4 antibody, which completed phase I clinical trial to treat to human v-domain immunoglobulin suppressor of T-cell activation (VISTA). The company was formerly known as Antisense Therapeutics Limited and changed its name to Percheron Therapeutics Limited in December 2023. Percheron Therapeutics Limited was incorporated in 2000 ...

• Industry: Pharmaceutical Preparations
• Founded: 2000
• Employees: 8
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: AWY0

Financial Performance

In fiscal year 2026, Percheron Therapeutics's revenue was 843,600, a decrease of -53.16% compared to the previous year's 1.80 million. Losses were -4.79 million, -67.89% less than in 2025.

Financial numbers in AUD

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Aug 27, 2026

Data Sources Report a data error